Mark C. Eagleton
Impact in
-
- Bone health and treatments
- Inflammatory Biomarkers in Disease Prognosis
- Cytokine Signaling Pathways and Interactions
- Chemokine receptors and signaling
Papers in
- Oncology 7
- Bone health and treatments 6
- Chemokine receptors and signaling 1
- Cancer Treatment and Pharmacology 1
- Cytokine Signaling Pathways and Interactions 1
- Cancer-related Molecular Pathways 1
-
- Bone Metabolism and Diseases 4
- Co-authors
- Katherine N. Weilbaecher (7 shared papers)David Piwnica‐Worms (5 shared papers)Angela C. Hirbe (5 shared papers)Julie L. Prior (4 shared papers)Özge Uluçkan (5 shared papers)Elizabeth A. Morgan (3 shared papers)Anthony J. Apicelli (2 shared papers)Desiree H. Floyd (4 shared papers)
- Journals
- Journal of Cellular Biochemistry (1 paper)Cancer Treatment Reviews (1 paper)Bone (1 paper)Proceedings of the National Academy of Sciences (1 paper)Journal of Biological Chemistry (1 paper)
- Partner nations
- United StatesIndiaUnited Kingdom
In The Last Decade
Mark C. Eagleton
7 papers receiving 275 citations
Peers
Comparison fields: 5 of 58
- Oncology 181
- Hematology 39
- Orthopedics and Sports Medicine 29
- Immunology 58
- Immunology and Allergy 16
Countries citing papers authored by Mark C. Eagleton
This map shows the geographic impact of Mark C. Eagleton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark C. Eagleton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark C. Eagleton more than expected).
Fields of papers citing papers by Mark C. Eagleton
This network shows the impact of papers produced by Mark C. Eagleton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark C. Eagleton. The network helps show where Mark C. Eagleton may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark C. Eagleton, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2006 | 76 | |
| 2 | 2009 | 54 | |
| 3 | 2008 | 48 | |
| 4 | 2007 | 44 | |
| 5 | 2008 | 37 | |
| 6 | 2010 | 18 | |
| 7 | 2008 | 2 |
About Mark C. Eagleton
Mark C. Eagleton is a scholar working on Oncology, Molecular Biology, Radiology, Nuclear Medicine and Imaging, Pharmacology and Pulmonary and Respiratory Medicine, having authored 7 papers that have together received 279 indexed citations. Recurring topics across this work include Bone health and treatments (6 papers), Bone Metabolism and Diseases (4 papers), Radiopharmaceutical Chemistry and Applications (2 papers), Chemokine receptors and signaling (1 paper), Cancer Treatment and Pharmacology (1 paper), Cytokine Signaling Pathways and Interactions (1 paper), Prostate Cancer Treatment and Research (1 paper) and Cancer-related Molecular Pathways (1 paper). The work is most often cited by research in Oncology (181 citations), Hematology (39 citations), Orthopedics and Sports Medicine (29 citations), Immunology (58 citations) and Immunology and Allergy (16 citations). Mark C. Eagleton has collaborated with scholars based in United States, India and United Kingdom. Frequent co-authors include Katherine N. Weilbaecher, David Piwnica‐Worms, Angela C. Hirbe, Julie L. Prior, Özge Uluçkan, Elizabeth A. Morgan, Anthony J. Apicelli, Desiree H. Floyd, Hongju Deng and Kathryn Trinkaus. Their work appears in journals such as Journal of Cellular Biochemistry, Cancer Treatment Reviews, Bone, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.